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We investigated the effect ofinsulin~likc grolllth hctor II (IGF.11) and insulin-like growth factor binding protein-I (IGFBP-1) on 3.0.methyl&cose 
transport in incubntcd human skeletal muscle strips. Increasing physiological concentrations of IGF.11 stimulared glucose transport in a dose- 
dependent manner. Glucose transport was maximally stimulated in the presence of 100 @ml (I 3.4 nM) of IGF-II, whichcorresponded to thcell’ect 
obtained by lOOpU/tnl (0.6 nM) of insulin. Expesure of muscle strips to IGFDP-I (500 n&ml) inhibited the maximal effect of IGF-11 on glucose 
transport by 40%. Thus, it is conceivable that IGF-II and IGFEWl arc physiological regulators ofthc glucose transport process in human skeletal 
muscle, 
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1. INTRODUCTION 
The IGF-I and IGF-II polypeptides are insulin-like 
growth factors which have structural homology with 
insulin [I], Although the major effects of the IGF’s are 
on cell replication and differentiation [I ,2], the IGF’s 
demonstrate ffects imilar to insulin on glucose metab- 
olism [3,4]. IGF-I exerts a stimulatory effect on glucose 
transport in rat 141 and human skeletal muscle [S]. Fur- 
thermore, in rats, glucose uptake is increased in insulin 
target tissue, including adipose tissue, heart muscle and 
striated muscle [6-81 in response to IGF-II exposure. 
One striking difference between the IGF’s and insulin 
is the existence of a f’dmily of six specific serum insulin- 
like growth factor binding proteins (IGFBP’s) 191. In the 
circulation, IGF’s are mainly associated with a 150 kDa 
binding complex which contains the IGF binding sub- 
unit, IGFBP-3 [lo], or are coupled to the IGFBP-I in 
smaller quantities [ll]. Circulatory IGF’s originate in 
the liver, and in their free form, can be transported to 
the target issues [!2]. When the IGF’s are bound to the 
IGFBP’s, their distribution to the target tissues appears 
to be modulated [I 31. Furthermore, at the target issue, 
the IGFBP’s modulate the action of the IGF’s by inter- 
acting with the receptor binding processes [2,14]. In 
human target tissue, the interaction between the 
IGFBP’s and IGF-11 has not been defined. 
IGF-I and II operate as hypoglycemic peptides which 
may play a functional role in the maintenance of glyce- 
mia [3,!5]. In response to physical activity, a temporary 
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increase in the circulatory level of IGF-II has been ob- 
served, and may contribute to the in vivo increase in 
glucose transport activity associated with exercise [16]. 
Here we investigate the response of the human skeletal 
muscle glucose transport process to IGF-II. Since the 
biological activity of the IGF’s may be altered by their 
binding to the IGFBP peptides, we also investigated the 
interaction between IGFBP-I and IGF-II on skeletal 
muscle glucose transport. For these purposes, we em- 
ployed an open muscle biopsy technique to obtain 
human muscle specimens [l?] suitable for in vitro incu- 
bations [ 181. 
2. MATERIALS AND METHODS 
2.1 , Slhjrcrs 
Fifteen healthy malt volunteers (age. 28.7 2 I .5 year; weight. 75.2 
+ 1.9 kg; height, 179.6 t- 3.9 cm; body mass index, 23.5 f 0.6 kg/m’) 
participated in IIIU study. None ol’ the subjects wcrc taking medica- 
tions, or had a family history of metabolic disorders. Thcaubjects were 
moderately engaged in physical activity, 2-3 times per week. and all 
were non-smokers. The study protocol was rcvicwcd and approved by 
Ihe institutional ethical commiltcee of the Karolinska Institute. The 
nature. purpose, and possible risks of the study were carefully ex- 
plained to each subject before giving their consent o panicipatc. 
2.2. Open rtrusclc biupsy procedure 
The subjects reported to the laboratory following an overnight fast. 
Local anneslhesia (Mcpivakain chloride 5 m&ml) was admiliistered 
and a 4.cm incision was made 15 cm above the proximal border of the 
patcila. Thereafter. the skin and fascia wcrc rellectcd to expose the 
intact muscle tibers of the vastus lateralis portion of the quadriceps 
fcmoris muscle [I 71. Two muscle spccimcns (-250 mg) wcrc clamped 
al resting length in viva, excised. and immedialely tmnsfcrrcd 10 a 
beaker which contained oxygenated Krcbs-Hcnselit (KHB) bicarbon- 
ate buflcr, 5 mM HEPES (N-2-Hydroxycthylpip’r~ine-N’-2-ct~~ane- 
sulphonic acid), 0.1% bovine serum albumin (RIA Grade, Fraction 
V), 38 mM mannitol and 2 mM pyruvarc. The IWO samples were 
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Fig. 1. IGF-II stimulated 3.O-methylglucose transport in human skel- 
etal muscle strips. Muscle strips from 7 subjects were incubated in 
vitro, in increasing concentrations of IGF-II and the rate of 3-O. 
methylglucose transport was determined as dcscribrd in section 2, 
Results rcprcsent a complete dose-response curve for each subject. 
Values arc means & S.E.M. *P c 0.05 vs. 0 @ml of IGF-II, *P < 0.01 
vs. 0 @ml of IGF-II. 
transported tothe laboratory (<2 min). whereafter 5-8 smaller muscle 
strips (-20 mg) were dissected free from each sample, mounted on 
plcxi-plnss clamps (0.9 cm wide) and removed from tbc tissue specimen 
as described earlier [17.18]. 
Immediately following tissue preparation, the muscle strips were 
placed in individual covered flasks, in a shaking incubator (I 10 times/ 
min) maintained at 35°C. All media were prepared aily from a KHB 
stock (pH 7.4), which was gassed with 95% 0:/S% CO:, Following 
dissection, the muscle strips were allowed to recover for IO min in 
KHB containing 2 mM pyruvate and 35 mM mannitol, Thetcaflcr, the 
muscle strips were transferred to pre-incubation media which con- 
taiacd KHB, 5 mM glucose, and 35 mM mannitol. The muscle strips 
were exposed to IGF-II, insulin, or IGFBP-I for 60 min as described 
in Table I and Fig. 1. Media concentrations of IGF-11, insulin, or 
IGFBP-I were maintained throughout the entire incubation protaco!. 
Glucose was rinsed from the extracetlular space of the muscle strips 
by means of a IO min exposure 10 a KHB solution which contained 
40 mM mannitol. Thereafter, 3.U-methylglucosc transport activity 
was assessed in the muscle strips during a 20 min incubation in KHR 
medium whereby 5mM 3.U[‘H]mcthylglucosc (437yCi/mmol) and 35 
mM [“Clmannitol (8 @Zi/mmol) were substituted for unlabeled glu- 
cose and mannitol, respectively. Following incubation, the muscles 
were processed by the method escribed by Wallberg-Henriksson a d 
Holloszy [ 191. 
2.4. IGF-II arrd IGFBP-I relme 
Basal pre-incubation media (0 ng/ml IGF-II) was collected from six 
muscle strips following the 60.min pre-incubation tzatmcnt. The 
media was pooled (total I2 ml) and dialyzed in a 1000 MW cutoff 
dialysis tube against 0.01 M acetic acid, The dialysate was lyophilized 
and re-suspended in I M acetic acid. The solution was then chromato- 
graphed on a Sephadex G 50 column (0.9 x 30 cm) (FPLC equipment, 
Pharmacia, Uppsala, Sweden) and cluted with I M acetic acid, and 
0.02 M NaCl (Row rate 0.5 ml/min nt 4OC) to separate the IGF-II and 
the IGFBP’s fractions. Tne IGF-II immunorcactivity in the IGF frac- 
tion (& 0.32.4l.85) was determined by radioimmunoassay [20]. The 
IGFSP fraction (K,O.O-O,32) was analyzed by Western ligand blotting 
as originally described by Hossenlopp et al, [21] with minor modifica- 
tions. Briefly, approximately /5 the original volume was processed by 
SDS-PAGE (-2.4 ml), and trans.bloued to a nitrocellulosc filter 
paper. After blocking the filter paper with albumin, the binding pro- 
teins were probed with ‘?‘I-labeled IGF-II and visualized on X-ray 
film, The detection limit for lhe Western l&and blotting is in thl: order 
of IO ng of IGFBP-I. 
2.5. An&ric iL!c~llii~uc.~ U&l cllelt~icu~s 
Plasma glucose was analyzed with a Beckman Glucose Analyzer 
(Beckman Instrument Inc., Fullerton, CA, USA). Serum insulin con- 
centration was determined by stand& radioimmunoassuy (Phade- 
scph insulin RIA method, Pharmacia, Uppsala, Sweden), The lower 
limit of sensitivity of this method is 3.0 yU/ml of insulin. 
All chemicals, unless tated otherwise, were of the highesl purity and 
obtained from Sigma Chemical Company (St. Louis, MO, USA), 
Recombinant human IGF-II and IGFBP-I were generous gifts pro- 
vided by Kabigen. Kabi Pharmacia (Stockholm, Sweden), The insulin 
(Actrapid) was a product of Novo Industry A/S. Copcnhagcn, Wen- 
mark. All radioactive products were purchased from New England 
Nuclear (Boston, MA, USA). 
The statistical signilicance of the differences bclween the effect of 
IGF-II on glucose transport in human skeletal muscle sirips incubated 
in the presence or absence of IGFBP-I was determined by Student’s 
paired r-test. A one-way analysis of variance (ANOVA) was employed 
to evaluate the diffcrenccs between various concentrations of IGF-II. 
When the ANOVA resulted in a significant F-value, the difference 
between the means was identified by the Newman-Keuls test. A signif- 
icance level of P < 0.05 was employed. Results arc expressed as means 
!: 5.E.M. 
3. RESULTS 
3.1. Subject chructeristics 
The participants exhibited normal fasting plasma glu- 
cose and serum insulin values of 5.01 f 0.10 mM and 
6.29 1 0.57 ~U/ml, respectively. 
3.2. Retcuse of IGF-II mtd IGFBP-I to mediu 
Pooled basal (0 ng/ml of IGF-11) pre-incubation 
media, collected from six muscle strips following 60 min 
incubation, contained 0.6 n&l of lGF-II. The observ- 
ance of IGF-II in the basal media indicates that each 
muscle strip released approximately 1.2 ng of IGF-II 
into the media during the basal incubation period. This 
release corresponded to -6% of the lowest concentra- 
tion of IGF-II tested (10 ng/ml), No IGFBP’s could be 
detected in the pooled media when assessed by Western 
ligand blot analysis. Thus, the concentration of IGFBP- 
1 in the pooled pre-incubation media was less than 4 
ngiml. 
3.3. EfJect of- IGF-I1 on ghcose mmporr 
The basal rate of 3-O-methylglucose transport in the 
incubated skeletal muscle strips increased from 0.95 f 
0.06 (H = 7) to 1.74 + 0.17 (12 = 7) ~mol*rnl-‘ah-’ (P < 
0.01) when IGF-II at 100 @ml (13.4 nM) was present 
in the media. No further increase in the IGF-11 stimu- 
lated glucose transport process was observed in the 
presence of 1000 ng!ml(l34 nM) of IGF-II when com- 
pared to the effect elicited by 100 @ml of IGF-II (1.87 
& 0.24 ~rnol~rnl-‘ah” for 1,000 ng/ml of IGF-II; n = 7>. 
Thus, a maximal effect of IGF-II on the rate of glu~~~~:~ 
transport was obtained at a concentration of 100 n&, :: 
380 
Volume 307, number 3 FEBS LETTERS August 1992 
A dose dependent relationship for physiological con- 
centrations of ICF-II was established by exposing mus- 
cle strips to increasing concentrations of IGF-II (0, 10, 
30 and 100 ng/ml). The rate of 3-O-methylglucose trans- 
port in the skeletal muscle strips increased in a dose- 
dependent manner (Fig. I). Basal glucose transport in- 
creased 1.4.fold (P < 0.05) when stimulated with IGF-II 
at a concentration of 30 ng/ml[4 nM), whereas 10 @ml 
(1.3 nM) of IGF-II failed to elicit an effect. IGF-II, at 
a concentration of 100 ndml (13.4 nM), stimulated the 
glucose transport system (1.47 f 0.19 ~mol~ml-‘~h-J, P 
< 0.01) to the same extent as observed in the presence 
of 100 pU/ml (0.6 nM) of insulin (1.51 1 0.18 
~mol.ml-‘*h-l, P < O.Ol), 
3,4, Effect of IGFBP-I 011 glrrcose transport 
Exposure of muscle strips to IGFBP-1 did not alter 
the basal rate of glucose transport in human skeletal 
muscle strips (Table I). In the presence of IGF-II (100 
nglml), an equimolar concentration of IGFEP-1 (500 
@ml) (20 nM) inhibited the increase in IGF-II stimu- 
lated glucose transport by 40% (P c 0.05) (Table I). 
4. DISCUSSION 
In this report, we provide evidence which indicates 
that IGF-II is a regulator of the glucose transport proc- 
ess in human skeletal muscle. During in vitro incuba- 
tion, increasing concentrations of free IGF-II stimu- 
lated skeletal muscle glucose transport in a dose-de- 
pendent manner. The maximal effect of IGF-II 
observed at 100 ng/ml(l3.4 nM), corresponded with the 
stimulatory effect of insulin (100 @/ml. 0.6 nM) on 
skeletal muscle glucose transport. Thus, as a stimulator 
of the skeletal muscle glucose transport process, IGF-II 
is approximately 20 times less potent than insulin. 
In adult serum, the molar concentrations of IGF-I 
and IGF-II are lo- to 100.fold higher than required for 
their effect in vitro [22]. Of the total serum IGF-I’s, the 
free form of IGF-I has been estimated to be in the order 
Table I 
EtTcct of IGFBP-1 on the rateof basal and IGF-II stimulated glucose 
transport in human skeletal muscle 
Media Glucose transport 
(,umol~ml-‘*h-l) 
No IGFBP-1 IGFBP-! (500 q/ml) 
Basal 0.88 I* 0.14 0.93 -+ 0.11 
iGF-II (100 W/ml) 1.78 s 0.28 1.44 r 0.19’ 
Of the two insulin-like growth factors, the biological 
function of IGF-1 is more clearly defined [1,26]. The 
biological action of IGF-I on human skeletal muscle 
glucose transport has been reported to elicit a response 
similar to that observed by insulin [S]. In human skeletal 
muscle there is cross-reactivity between the structurally 
homologous insulin and IGF-I receptors, whereby the 
insulin-like effects of IGF-I have been demonstrated to 
be mediated [5,8,28,29]. Results from hormone dis- 
placement experiments reveal that IGF-I stimulates glu- 
cose transport hrough its specific receptor and not sim- 
ply in association with the insulin receptor [S]. Although 
IGF-II receptors are present in various tissues, the 
physiological role of IGF-11 in adult humans has not 
been clarified. In the present report, physiological con- 
centrations of IGF-11 appear to regulate the skeletal 
muscle glucose transport system, nevertheless, the cellu- 
lar mechanism by which this polypeptide operates re- 
mains to be elucidated. Almost all of the reported in 
vitro and in viva effects of IGF’s have been described 
to be mediated over the IGF-I receptor [26]. Thus, it is 
likely that the effects of IGF-II on the glucose transport 
are mediated in part by the IGF-I receptors. 
Values arc means I S.E.M. Torn = 6 subjects. One observation was 
obtained for all expcrimcntnl conditions for each of the 6 subjects. 
Skeletal muscle strips were prepared and incubated in the prcacncc or 
absence of insulin-like Browth factor II (IGF-II) with the addition or 
omission of insulin-like growth factor binding protein I (IGFBP-I) as 
outlined in section 2. ‘P < 0.05 vs. No IGFBP-1, IGF’s kave been described as hypoglycemic geptides 
of l-S% [15]. Since the total serum concentration of 
IGF-II is approximately 800 @ml, the estimated free 
form of IGF-II, based on the reported percentage of 
free IGF-I, would correspond to 8-40 ng. We have 
observed astimulatory effect of IGF-II on skeletal mus- 
cle glucose transport in the presence of 30 @ml. Thus, 
our data indicates that physiological concentrations of 
IGF-II activate the human muscular glucose transport 
process. 
The liver is the main source of the circulatory IGF’s, 
however, the IGF’s are also produced locally in many 
tissues including skeletal muscle [23,24]. Although the 
extracellular concentrations of the IGF’s in the target 
tissues are not known, the possibility remains that the 
IGF’s may accumulate in the extracellular space of the 
musculature, thus resulting in a high concentration of 
IGF’s at the site of the muscle. 
Elevated or depressed levels of the IGFBP’s will po- 
tentially influence the metabolic effects of the 1GF’s. 
When the IGF’s are coupled to the binding proteins, the 
binding of the hormone to the insulin or IGF receptor 
is inhibited [25] and the stimulatory effects of the IGF’s 
on glucose mctaboliem are altered [26]. Evidence for an 
inhibitory effect of IGFBP-1 on the IGF-II stimulated 
increase in skeletal muscle glucose transport is pre- 
sented in this report (Table I). Factors which alter the 
regulation of the IGFBP’s must be considered when 
investigating the effects of the IGF’s. Insulin is reported 
to play a regulatory role in the concentration of IGFBP- 
I [273. Consequently, fluctuations in the concentration 
of binding proteins as a result of alterations in the serum 
insulin level may modify the physiological effect of 
IGF’s. 
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[3,15,26] which as reported here, and by others [5], have 
profound effects on glucose metabolism in skeletal mus- 
cle from healthy subjects. Although insulin is the pri- 
mary stimulator of skeletal muscle glucose transport, 
the IGF’s may be notable contributors to the regulation 
of glycemia in vivo. Patients with non-insulin-depend- 
ent diabetes mellitus and obesity demonstrate decreased 
insulin fl8,30] and IGF-I [5] stimulated skeletal muscle 
glucose transport. The effects of IGF-II on skeletal 
muscle glucose metabolism in patients with peripheral 
insulin resistance remains to be established. 
In conclusion, the present study reveals that physio- 
logical concentrations of IGF-II stimulate the glucose 
transport process in healthy, human skeletal muscle. 
Furthermore, IGFBP-1 appears to play a counter-regu- 
latory role in the IGF-II stimulated glucose transport. 
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